Tramiprosate

Product Description

Tramiprosate is a sulfated glycosaminoglycan (sGAG) mimetic that targets soluble amyloid β (Aβ) and maintains Aβ in a non-fibrillar form. Decreases Aβ42-induced neuronal death and inhibits amyloid deposition in vitro. Decreases brain amyloid plaque load by 30%, increases tau polymerization and is brain penetrant. Also a GABA analog that protects against the convulsant and cytotoxic activity of kainic acid in vivo.

Solubility

Preparing Stock Solutions for Tramiprosate

The following data is based on the product molecular weight 139.17

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	7.19 mL	35.93 mL	71.85 mL
5 mM	1.44 mL	7.19 mL	14.37 mL
10 mM	0.72 mL	3.59 mL	7.19 mL
50 mM	0.14 mL	0.72 mL	1.44 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Gervais Targeting soluble Aβ peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol.Aging 2007 PMID: 16675063
• Santa-Maria Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol.Neurodegen.
• Fariello Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid. Neurology 1982 PMID: 7199633